GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BIMI Holdings Inc (STU:63N) » Definitions » Quality Rank

BIMI Holdings (STU:63N) Quality Rank


View and export this data going back to . Start your Free Trial

What is BIMI Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

BIMI Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of BIMI Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


BIMI Holdings (STU:63N) Business Description

Traded in Other Exchanges
Address
Chongqing Corporation Avenue, 9th Floor, Building 2, Yuzhong District, Chongqing, CHN, 400010
BIMI International Medical Inc is a healthcare product and provider, offering a broad range of healthcare products and related services and operates private hospitals in China. The company is engaged in four business segments, Pharmaceuticals wholesale, Medical devices wholesale, Medical services, and Pharmacy retail. It generates maximum revenue from the pharmaceuticals wholesale segment. It mainly sources its products from large state-owned pharmaceutical manufacturers and wholesalers and mid-sized or small private pharmaceutical manufacturers and wholesalers. The Company's revenues were generated in the PRC.